Hyperpolarized 13C-pyruvate Metabolic MRI With Traumatic Brain Injury

PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 26, 2023

Primary Completion Date

November 26, 2026

Study Completion Date

November 26, 2027

Conditions
Traumatic Brain InjurySubarachnoid Hemorrhage
Interventions
DRUG

Hyperpolarized 13C-Pyruvate

"Hyperpolarized Pyruvate (13C) Injection, containing spin-polarized (hyperpolarized) \[13C\]pyruvate, is being studied as a diagnostic agent in combination with 13C spectroscopic MR imaging. The aim is to visualize \[13C\]pyruvate and its metabolites and thereby distinguish between anatomical areas with normal vs. abnormal metabolism, which should be useful in diagnosing and characterizing, for example, traumatic brain injury.~Hyperpolarized Pyruvate (13C) Injection and \[13C\]pyruvate are general terms used throughout this brochure, which refer to all 13C labeling patterns, such as \[1- 13C\]pyruvate, \[2- 13C\]pyruvate and \[1,2- 13C\]pyruvate. From biological and safety standpoints, pyruvate with each of the labeling patterns behaves identically in the human body \[Koletzko et al., 1997\]."

Trial Locations (1)

21201

RECRUITING

University of Maryland Baltimore, Baltimore

All Listed Sponsors
lead

University of Maryland, Baltimore

OTHER